For example, androgen receptor (AR) variants that drive resistance to standard antagonists remain susceptible to degradation‐based strategies [16, 17], and transcription factors such as STAT3—long considered among the most challenging cancer targets—are now tractable through systematic degradation [18]. This evidence concerns the gene AR and cancer.